Nadine Benhamouda

ORCID: 0000-0002-0438-924X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • SARS-CoV-2 and COVID-19 Research
  • CAR-T cell therapy research
  • COVID-19 Clinical Research Studies
  • Angiogenesis and VEGF in Cancer
  • Colorectal Cancer Treatments and Studies
  • Colorectal Cancer Surgical Treatments
  • Inflammatory Biomarkers in Disease Prognosis
  • Renal cell carcinoma treatment
  • vaccines and immunoinformatics approaches
  • Head and Neck Cancer Studies
  • Cancer Research and Treatments
  • Ferroptosis and cancer prognosis
  • Mast cells and histamine
  • Cervical Cancer and HPV Research
  • HIV Research and Treatment
  • Cancer Cells and Metastasis
  • T-cell and B-cell Immunology
  • Pancreatic and Hepatic Oncology Research
  • Nanoplatforms for cancer theranostics
  • Single-cell and spatial transcriptomics
  • Colorectal and Anal Carcinomas
  • Esophageal Cancer Research and Treatment

Inserm
2013-2025

Hôpital Européen Georges-Pompidou
2015-2025

Université Paris Cité
2010-2025

Paris Cardiovascular Research Center
2012-2025

Sorbonne Paris Cité
2012-2025

Assistance Publique – Hôpitaux de Paris
2012-2024

Hôpital Européen
2012-2024

Institut Gustave Roussy
2022

Université Sorbonne Nouvelle
2021

Sorbonne Université
2012-2021

Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which characterized by expression of inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and progressive loss function. The recent development therapies targeting PD-1 CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, regulation expression, thereby...

10.1084/jem.20140559 article EN The Journal of Experimental Medicine 2015-01-19

Head and neck cancers positive for human papillomavirus (HPV) have a more favorable clinical outcome than HPV-negative cancers, but it is unknown why this the case. We hypothesized that prognosis was affected by intrinsic features of HPV-infected tumor cells or differences in host immune response. In study, we focused on comparison regulatory Foxp3(+) T programmed death-1 (PD-1)(+) microenvironment tumors were negative HPV, two groups matched various biologic parameters. HPV-positive head...

10.1158/0008-5472.can-12-2606 article EN Cancer Research 2012-11-08

Multitarget antiangiogenic tyrosine kinase inhibitors (TKI) have been shown to reduce regulatory T cells (Treg) in tumor-bearing animals and patients with metastatic renal carcinomas. However, a direct role of the VEGF-A/VEGFR pathway inhibition this phenomenon is matter debate molecular mechanisms leading Treg modulation setting not explored date. proportion, number, proliferation were analyzed by flow cytometry peripheral blood colorectal cancer (mCRC) treated bevacizumab, monoclonal...

10.1158/0008-5472.can-12-2325 article EN Cancer Research 2012-10-30

Comparative studies suggest that stem cells committed to a cardiac lineage are more effective for improving heart function than those featuring an extra-cardiac phenotype. We have therefore developed population of human embryonic cell (ESC)-derived progenitor cells. Undifferentiated ESCs (I6 line) were amplified and cardiac-committed by exposure bone morphogenetic protein-2 fibroblast growth factor receptor inhibitor. Cells responding these cardio-instructive cues express the transcription...

10.1093/eurheartj/ehv189 article EN European Heart Journal 2015-05-19

Inhibitory receptors expressed by T cells mediate tolerance to tumor antigens, with coexpression of these exacerbating this dysfunctional state. Using the VectraR automated multiparametric immunofluorescence technique, we quantified intratumoral CD8+ coexpressing inhibitory PD-1 and Tim-3 from patients renal cell carcinoma (RCC). A second validation cohort measured same parameters cytometry. The percentage tumor-infiltrating correlated an aggressive phenotype a larger size at diagnosis....

10.1158/0008-5472.can-16-0274 article EN Cancer Research 2016-11-22

Abstract In the present report we have analyzed whether human normal cord blood‐derived mast cells (CBMC) could interact with bacterial products, especially lipopolysaccharide (LPS) from Escherichia coli and peptidoglycan (PGN) Staphylococcus aureus , known as Toll‐like receptor (TLR) 4 TLR2 agonists, respectively. We found that both LPS PGN induced significant release of not only tumor necrosis factor‐α (TNF‐α), but also IL‐5, IL‐10 IL‐13 by (MC). established stimulation CBMC or is mediated...

10.1002/eji.200323830 article EN European Journal of Immunology 2003-03-18

Background Resident memory T lymphocytes (T RM ) are located in tissues and play an important role immunosurveillance against tumors. The presence of prior to treatment or their induction is associated the response anti-Programmed cell death protein 1 (PD-1)/Programmed death-ligand (PD-L1) immunotherapy efficacy cancer vaccines. Previous work by our group others has shown that intranasal route vaccination allows more efficient these cells head neck lung mucosa, resulting better tumor...

10.1136/jitc-2020-001948 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2021-03-01

To investigate the presence and impact of spontaneous telomerase-specific CD4 T-cell responses in cancer patients.A multistep approach was used to design novel pan-HLA-DR-restricted peptides from telomerase. clones isolated patients were characterize polarization response. The response against telomerase monitored 84 metastatic non-small cell lung (NSCLC) before first-line chemotherapy (CT) using IFN-γ ELISPOT assay. Then we analyzed pretherapeutic T immunity on clinical outcome according...

10.1158/1078-0432.ccr-11-3185 article EN Clinical Cancer Research 2012-03-09

CD70 is a costimulatory molecule known to activate CD27-expressing T cells. CD27-CD70 interaction leads the release of soluble CD27 (sCD27). Clear-cell renal cell carcinoma (ccRCC) expresses highest levels among all solid tumors; however, clinical consequences expression remain unclear.Tumor tissue from 25 patients with ccRCC was assessed for and in situ using multiplex immunofluorescence. CD27+ T-cell phenotypes tumors were analyzed by flow cytometry their gene profile single-cell RNA...

10.1158/1078-0432.ccr-22-0905 article EN Clinical Cancer Research 2022-09-06

Mastocytosis is a rare neoplastic disease characterized by pathologic accumulation of tissue mast cells (MCs). often associated with somatic point mutation in the Kit protooncogene leading to an Asp/Val substitution at position 816 kinase domain this receptor. The contribution mastocytosis development remains unclear. In addition, clinical heterogeneity presented patients carrying same unexplained. We report that striking similarities human develops spontaneously transgenic mice expressing...

10.1084/jem.20050807 article EN The Journal of Experimental Medicine 2005-12-13

Abstract Background Immunotherapies targeting PD-1 and CTLA-4 are key components of the treatment metastatic clear cell renal carcinoma (mccRCC). However, they have distinct safety profiles resistance to can occur. We assess soluble TIM-3 (sTIM-3) in plasma mccRCC patients as a potential theranostic biomarker, well its source biological significance. Methods analyzed association between sTIM-3 overall survival (OS), tumor response, common clinical factors two cohorts treated with anti-PD-1...

10.1186/s13046-025-03293-y article EN cc-by Journal of Experimental & Clinical Cancer Research 2025-02-14

Metastatic melanoma can be treated with anti-PD-1 monotherapy or in combination anti-CTLA-4 anti-Lag3. However, therapy is associated a high risk of toxicity. Recently, we reported that plasma soluble CD27 (sCD27) levels reflect the intratumoral interaction CD70-CD27 and dysfunctional T cells tumor microenvironment renal cell carcinoma. In this study, first characterized expression CD70 tumors their vivo. We then significant association between baseline sCD27 resistance as assessed by...

10.1038/s44321-025-00203-9 article EN cc-by EMBO Molecular Medicine 2025-03-27

French National Agency for Research on AIDS and Viral Hepatitis's HIV-LIPO-5 vaccine includes five HIV-1 peptides, containing multiple CD8 CD4 T-cell epitopes coupled to a palmitoyl tail. Whether immunogenicity varies with the dose is unknown.HIV-negative volunteers were randomized receive at 50 microg/lipopeptide (N = 32), 150 500 33) or placebo 34) weeks 0, 4, 12 24. HIV-1-specific (interferon-gamma ELISpot peripheral blood mononuclear cells cultured days) responses (peripheral cell...

10.1097/qad.0b013e32833ce566 article EN AIDS 2010-07-12

The primary goal of immune monitoring with ELISPOT is to measure the number T cells, specific for any antigen, accurately and reproducibly between different laboratories. In assays, antigen-specific cells secrete cytokines, forming spots sizes on a membrane variable background intensities. Due subjective nature judging maximal minimal spot sizes, investigators come up numbers. This study aims determine whether statistics-based, automated size-gating can harmonize counts calculated We plated...

10.3390/cells4010021 article EN cc-by Cells 2015-01-09

Abstract Vaccination against coronavirus disease 2019 (COVID-19) relies on the in-depth understanding of protective immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We characterized polarity and specificity memory T cells directed SARS-CoV-2 viral lysates peptides determine correlates with spontaneous, virus-elicited, or vaccine-induced protection COVID-19 in disease-free cancer-bearing individuals. A disbalance between type 1 2 cytokine release was...

10.1158/2159-8290.cd-21-1441 article EN cc-by-nc-nd Cancer Discovery 2022-02-18

Objective The objective was to compare the safety and cellular immunogenicity of intradermal versus intramuscular immunization with an HIV-lipopeptide candidate vaccine (LIPO-4) in healthy volunteers. Methodology A randomized, open-label trial 24 weeks follow-up conducted France at six HIV-vaccine sites. Sixty-eight 21– 55–year-old HIV-uninfected subjects were randomized receive LIPO-4 (four HIV lipopeptides linked a T-helper–stimulating epitope tetanus-toxin protein) 0, 4 12, either...

10.1371/journal.pone.0000725 article EN cc-by PLoS ONE 2007-08-22
Coming Soon ...